Micromedic: Leading the Path to Introducing Novel Cancer Diagnostic Tools.
Micromedic is a publicly traded company listed on the Tel Aviv Stock Exchange (TASE: MCTC). The company focuses on the development and commercialization of cancer diagnostic products.
Since December 2011 the company is controlled by BioLight Life Sciences Investments (TASE: BOLT) realizing its clusters approach by forming a “Cancer Diagnostic Cluster”.
Clustering - Bringing highly innovative companies together “under one roof”, benefiting from significantly increased knowledge sharing, which leads to higher levels of successful innovation, as well as increased economies of scale and management capacity.
Leadership – Micromedic’s highly experienced and professional team, led by Israel Makov, has an outstanding track record in both Life Sciences and M&As. Bringing breadth of experience and depth of expertise to select the highest potential companies for investment, and to create the conditions for maximizing collaboration and innovation within the cluster.
Global Opportunities - Our extensive global network provides major competitive advantages in sourcing and executing transactions.
The Clusters strategy enables to facilitate communication and collaboration among researchers and management teams within each company, thus promoting exposure to new ideas and approaches, and laying the groundwork for a continuous process of cooperation and innovation. This strategy enables Micromedic to:
attract top-tier management and researchers
capture unique opportunities for strategic collaborations and financial investment
maximize the companies’ exposure to thought leaders, investors, and institutions
share best practices and expertise, leading to better performance
benefit from operational synergies and other cost savings
Micromedic creates additional value for investors through:
broader scope of innovation generated by the companies
enhanced deal flow
a broad and balanced investment portfolio
Cancer Diagnostics Cluster
Cancer diagnostics is a growing field that aims to meet a large and rapidly expanding need. Realizing BioLight’s Clusters Model, Micromedic is forming a cluster that manages the development of a variety of products across the cancer diagnostic value chain. From screening and risk identification, through diagnostics, personalized medicine, and monitoring disease recurrence, Micromedic seeks to identify projects that fill unmet needs in various cancer indications, and turn them into viable marketable products.